New hope for HER2+ breast cancer: experimental drug JSKN003 faces off against standard therapy

This phase 2 study tests whether a new drug called JSKN003 works better than the current standard therapy for people with HER2-positive breast cancer that has returned or spread. About 60 adults who have not had prior treatment for advanced disease will receive either JSKN003 or a combination of trastuzumab, pertuzumab, and docetaxel. The main goal is to see how many patients' tumors shrink significantly.